TSX : BCT.TO

BriaCell Therapeutics Corp.

$5.26 CAD

-$0.08 (-1.5%)

Volume
1.8K
Average Volume
13.26K
Market Capitalization
$9.91M
P/E Ratio
-0.31
Dividend Yield
0.00%
Price Target
Year High
$20.40
Year Low
$3.68
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.07
Company Overview

TSX

William V. Williams

Biotechnology

Healthcare

BCT.TO

17

CA

CAD

https://www.briacell.com

604-921-1810

107930307

N/A

Liquidity Metrics

0.00

7.07

7.07

1.92

0.00

Sales & Valuation

-$

0.00

1.13

-0.23

-4.28

Profitability

-$62.95

-$26.63M

0.00%

0.00%

-147.92%

-113.23%

P/E Metrics

-0.31

0.00

0.00

Analyst Price Target & Rating

Sell

2/5

1 Analysts

%

Poll Results

About BriaCell Therapeutics Corp. (TSX:BCT.TO) Stock

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agre ... ement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.

BriaCell Therapeutics Announces Pricing of Offering

2026-05-31 19:59:35

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares.

Frequently Asked Questions

What is the current BriaCell Therapeutics Corp. (BCT.TO) stock price?

BriaCell Therapeutics Corp.(TSX:BCT.TO) stock price is $5.26 in the last trading session. During the trading session, BCT.TO stock reached the peak price of $20.4 while $3.68 was the lowest point it dropped to. The percentage change in BCT.TO stock occurred in the recent session was --1.5% while the dollar amount for the price change in BCT.TO stock was -$0.08.

BCT.TO's industry and sector of operation?

The TSX listed BCT.TO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BCT.TO?

Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board
Miguel A. Lopez-Lago | Chief Scientific Officer
William V. Williams | Chief Executive Officer, President & Director
Gadi Levin | Chief Financial Officer & Corporate Secretary
Giuseppe Del Priore | Chief Medical Officer

How many employees does BCT.TO have?

Number of BCT.TO employees currently stands at 17. BCT.TO operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.

Link for BCT.TO official website?

Official Website of BCT.TO is: https://www.briacell.com

How do I contact BCT.TO?

BCT.TO could be contacted at phone #604-921-1810 and can also be accessed through its website. BCT.TO operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.

How many shares of BCT.TO are traded daily?

The average number of BCT.TO shares traded daily for last 3 months was 13.26K.

What is the market cap of BCT.TO currently?

The market value of BCT.TO currently stands at $9.91M with its latest stock price at $5.26